Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 301

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

Socié, Gérard, Schmoor, Claudia, Bethge, Wolfgang A., Ottinger, Hellmut D., Stelljes, Matthias, Zander, Axel R., Volin, Liisa, Ruutu, Tapani, Heim, Dominik A., Schwerdtfeger, Rainer, Kolbe, Karin, Mayer, Jiri, Maertens, Johan A., Linkesch, Werner, Holler, Ernst, Koza, Vladimir, Bornhäuser, Martin, Einsele, Hermann, Kolb, Hans-Jochem, Bertz, Hartmut, Egger, Matthias, Grishina, Olga, Finke, Jürgen, for the ATG-Fresenius Trial Group·2011·Blood

Abstract

Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the control group (hazard ratio [HR] = 1.21, P = .47, and HR = 0.68, P = .18), respectively. This nonsignificant reduction in nonrelapse mortality without increased relapse risk led to an overall survival rate after 3 years of 55.2% in the ATG-F group and 43.3% in the control group (HR = 0.84, P = .39, nonsignificant). The HR for receiving immunosuppressive therapy (IST) was 0.31 after ATG-F (P < .0001), and the 3-year probability of survival free of IST was 52.9% and 16.9% in the ATG-F versus control, respectively. The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate. ATG-F prophylaxis reduces cGVHD morbidity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-01-329821

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 301

Metadata

Authors
Socié, G., Schmoor, C., Bethge, W. A., Ottinger, H. D., Stelljes, M., Zander, A. R., Volin, L., Ruutu, T., Heim, D. A., Schwerdtfeger, R., Kolbe, K., Mayer, J., Maertens, J. A., Linkesch, W., Holler, E., Koza, V., Bornhäuser, M., Einsele, H., Kolb, H.-J., Bertz, H., Egger, M., Grishina, O., Finke, J., & for the ATG-Fresenius Trial Group
Venue
Blood
Published
2011-06-09
Volume
117
Issue
23
Pages
6375-6382
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1980914191
Cited by
301
References
35
FWCI
17.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius. https://app.cochat.ai/papers/10.1182/blood-2011-01-329821
The paper
Socié, G., Schmoor, C., Bethge, W. A., Ottinger, H. D., Stelljes, M., Zander, A. R., Volin, L., Ruutu, T., Heim, D. A., Schwerdtfeger, R., Kolbe, K., Mayer, J., Maertens, J. A., Linkesch, W., Holler, E., Koza, V., Bornhäuser, M., Einsele, H., Kolb, H.-J., . . . for the ATG-Fresenius Trial Group. (2011). Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius. Blood. https://doi.org/10.1182/blood-2011-01-329821

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.